Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,031.15 USD
-14.83 (-1.42%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $1,056.00 +24.85 (2.41%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
REGN 1,031.15 -14.83(-1.42%)
Will REGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
Other News for REGN
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Sanofi to highlight skin disease treatments at Amsterdam conference
Intellia: Exciting Promise Of First In Vivo Gene Therapy Makes Bull Case
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Amgen stock slides 5% as analysts weigh in on drug study results (update)